177 related articles for article (PubMed ID: 29162447)
1. Co-administration of liposomal fasudil and tissue plasminogen activator ameliorated ischemic brain damage in occlusion model rats prepared by photochemically induced thrombosis.
Fukuta T; Yanagida Y; Asai T; Oku N
Biochem Biophys Res Commun; 2018 Jan; 495(1):873-877. PubMed ID: 29162447
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil.
Fukuta T; Asai T; Sato A; Namba M; Yanagida Y; Kikuchi T; Koide H; Shimizu K; Oku N
Int J Pharm; 2016 Jun; 506(1-2):129-37. PubMed ID: 27107903
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke.
Fukuta T; Asai T; Yanagida Y; Namba M; Koide H; Shimizu K; Oku N
FASEB J; 2017 May; 31(5):1879-1890. PubMed ID: 28082354
[TBL] [Abstract][Full Text] [Related]
4. Cerebroprotective effects of TAK-937, a novel cannabinoid receptor agonist, in permanent and thrombotic focal cerebral ischemia in rats: therapeutic time window, combination with t-PA and efficacy in aged rats.
Murakami K; Suzuki M; Suzuki N; Hamajo K; Tsukamoto T; Shimojo M
Brain Res; 2013 Aug; 1526():84-93. PubMed ID: 23791950
[TBL] [Abstract][Full Text] [Related]
5. Treatment of stroke with liposomal neuroprotective agents under cerebral ischemia conditions.
Fukuta T; Ishii T; Asai T; Sato A; Kikuchi T; Shimizu K; Minamino T; Oku N
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):1-7. PubMed ID: 26455340
[TBL] [Abstract][Full Text] [Related]
6. [Development of Biomembrane-mimetic Nanoparticles for the Treatment of Ischemic Stroke].
Fukuta T
Yakugaku Zasshi; 2021; 141(9):1071-1078. PubMed ID: 34471008
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotection by intrathecal application of liposome-entrapped fasudil in a rat model of ischemia.
Takanashi Y; Ishida T; Kirchmeier MJ; Shuaib A; Allen TM
Neurol Med Chir (Tokyo); 2001 Mar; 41(3):107-13; discussion 113-4. PubMed ID: 11372552
[TBL] [Abstract][Full Text] [Related]
8. Epigallocatechin Gallate Extends the Therapeutic Window of Recombinant Tissue Plasminogen Activator Treatment in Ischemic Rats.
You YP
J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):990-7. PubMed ID: 26851971
[TBL] [Abstract][Full Text] [Related]
9. Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model.
Satoh S; Toshima Y; Hitomi A; Ikegaki I; Seto M; Asano T
Brain Res; 2008 Feb; 1193():102-8. PubMed ID: 18187127
[TBL] [Abstract][Full Text] [Related]
10. Fasudil and ozagrel in combination show neuroprotective effects on cerebral infarction after murine middle cerebral artery occlusion.
Koumura A; Hamanaka J; Kawasaki K; Tsuruma K; Shimazawa M; Hozumi I; Inuzuka T; Hara H
J Pharmacol Exp Ther; 2011 Jul; 338(1):337-44. PubMed ID: 21493751
[TBL] [Abstract][Full Text] [Related]
11. A combined treatment with tacrolimus (FK506) and recombinant tissue plasminogen activator for thrombotic focal cerebral ischemia in rats: increased neuroprotective efficacy and extended therapeutic time window.
Maeda M; Furuichi Y; Ueyama N; Moriguchi A; Satoh N; Matsuoka N; Goto T; Yanagihara T
J Cereb Blood Flow Metab; 2002 Oct; 22(10):1205-11. PubMed ID: 12368659
[TBL] [Abstract][Full Text] [Related]
12. Applications of Liposomal Drug Delivery Systems to Develop Neuroprotective Agents for the Treatment of Ischemic Stroke.
Fukuta T; Ishii T; Asai T; Oku N
Biol Pharm Bull; 2019; 42(3):319-326. PubMed ID: 30828062
[TBL] [Abstract][Full Text] [Related]
13. Baicalin Attenuates Blood-Brain Barrier Disruption and Hemorrhagic Transformation and Improves Neurological Outcome in Ischemic Stroke Rats with Delayed t-PA Treatment: Involvement of ONOO
Chen H; Guan B; Chen X; Chen X; Li C; Qiu J; Yang D; Liu KJ; Qi S; Shen J
Transl Stroke Res; 2018 Oct; 9(5):515-529. PubMed ID: 29275501
[TBL] [Abstract][Full Text] [Related]
14. IMM-H004 prevents toxicity induced by delayed treatment of tPA in a rat model of focal cerebral ischemia involving PKA-and PI3K-dependent Akt activation.
Zuo W; Chen J; Zhang S; Tang J; Liu H; Zhang D; Chen N
Eur J Neurosci; 2014 Jun; 39(12):2107-18. PubMed ID: 24649933
[TBL] [Abstract][Full Text] [Related]
15. A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator.
Ishiguro M; Kawasaki K; Suzuki Y; Ishizuka F; Mishiro K; Egashira Y; Ikegaki I; Tsuruma K; Shimazawa M; Yoshimura S; Iwama T; Hara H
Neuroscience; 2012 Sep; 220():302-12. PubMed ID: 22710066
[TBL] [Abstract][Full Text] [Related]
16. Vessel Dilation Attenuates Endothelial Dysfunction Following Middle Cerebral Artery Occlusion in Hyperglycemic Rats.
Mu ZH; Jiang Z; Lin XJ; Wang LP; Xi Y; Zhang ZJ; Wang YT; Yang GY
CNS Neurosci Ther; 2016 Apr; 22(4):316-24. PubMed ID: 26842484
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic time window of tacrolimus (FK506) in a nonhuman primate stroke model: comparison with tissue plasminogen activator.
Furuichi Y; Maeda M; Matsuoka N; Mutoh S; Yanagihara T
Exp Neurol; 2007 Mar; 204(1):138-46. PubMed ID: 17169359
[TBL] [Abstract][Full Text] [Related]
18. Application of albumin prior to delayed thrombolysis reduces brain edema and blood brain barrier permeability in an embolic stroke model.
Lu HT; Zhao JG; Li MH; Li YD
Brain Res; 2012 Feb; 1438():75-84. PubMed ID: 22227456
[TBL] [Abstract][Full Text] [Related]
19. Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons.
Yamashita K; Kotani Y; Nakajima Y; Shimazawa M; Yoshimura S; Nakashima S; Iwama T; Hara H
Brain Res; 2007 Jun; 1154():215-24. PubMed ID: 17482584
[TBL] [Abstract][Full Text] [Related]
20. FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator.
Maeda M; Moriguchi A; Mihara K; Aoki T; Takamatsu H; Matsuoka N; Mutoh S; Goto T
J Cereb Blood Flow Metab; 2005 Jan; 25(1):108-18. PubMed ID: 15678117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
